Refractoryb Cell News Today

/PRNewswire/ -- Research conducted at Florida Cancer Specialists & Research Institute, LLC (FCS) was presented in the cutting-edge advancements being shared at...

ATA3431 Preclinical Data Demonstrates Superior In Vivo Anti-tumor Activity, Survival, and Functional Persistence Compared to Autologous CAR-T Benchmark No Observed Treatment-Related Toxicities or...

ATA3431 Preclinical Data Demonstrates Superior In Vivo Anti-tumor Activity, Survival, and Functional Persistence Compared to Autologous CAR-T BenchmarkNo Observed Treatment-Related Toxicities or AlloreactivityData Supports Advancement Into IND-Enabling StudiesTHOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeu...

The update followed results from the phase 1/2 EPCORE NHL-1 clinical trial evaluating the safety and preliminary efficacy of the drug, including in individuals with relapsed or refractory follicular lymphoma.

– Companies to Leverage Lead Product Candidate from IGM’s Proprietary IgM Antibody Platform with ZYNLONTA® for Novel Combination Therapy in Relapsed/Refractory B Cell NHL –– Phase 1 Trial Expected to be Initiated in 1Q23 –MOUNTAIN VIEW, Calif. & LAUSANNE, Switzerland--(BUSINESS WIRE)--IGM Biosciences, Inc. (Nasdaq:...

Data for Tuspetinib (HM43239) and Luxeptinib Accepted for Poster Presentation...

- Companies to Leverage Lead Product Candidate from IGM's Proprietary IgM Antibody Platform with ZYNLONTA for Novel Combination Therapy in Relapsed/Refractory B Cell NHL - - Phase 1 Trial Expected

09.08.2022 - TCR-CAR+ iPSC-derived CD8αβ T Cells Induced Complete and Durable Responses In Vivo in Systemic Leukemia Model Cell-surface Markers, Gene Transcription Profile, and In Vivo Anti-tumor Activity of TCR-CAR+ iPSC-derived CD8αβ T Cells Compared ... Seite 1